Business
Sutro Biopharma Announces Promising STRO-002 Interim Phase 1 Clinical Data in Ovarian Cancer and Presentation at the 2020 IGCS Annual Global Meeting
- Ongoing Data Further Demonstrate Promising Efficacy and Safety Profile in a Heavily Pretreated Patient Population Not Selected Based on Receptor Expression
About this update from Sutro Biopharma, Inc.
[{"type":"text","content":"- Ongoing Data Further Demonstrate Promising Efficacy and Safety Profile in a Heavily Pretreated Patient Population Not Selected Based on Receptor Expression\n - Conference Call Scheduled for Sept 9, 2020 at 5:30 p.m. Eastern Time\n\n\nSOUTH SAN FRANCISCO, Calif., Sept. 2, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO) today announced that Wendel Naumann, M.D., gynecologic oncologist at Levine Cancer Institute, along with Sutro executives, Bill Newell, Chief Executive Officer, Dr. Arturo Molina, Chief Medical Officer, Dr. Trevor Hallam, Chief Scientific Officer, and Edward Albini, Chief Financial Officer, will host a conference call on Wednesday, Sept. 9, 2020, at 5:30 p.m. EDT to discuss updated data from the company's ongoing Phase I dose escalation study of anti-Folate Receptor alpha (FRα) antibody-drug conjugate (ADC), STRO-002, in ovarian and endometrial cancer, with a data cut-off date of Aug. 31, 2020. \nAdditionally, the company announced a presentation at the upcoming 2020 xDigital Annual Global Meeting of the International Gynecologic Cancer Society (IGCS), being held Sept. 10-13, 2020. The virtual presentation will include Phase 1 dose escalation clinical data for STRO-002, with an efficacy data cut-off date of August 3, 2020. The abstract announcing the digital poster presentation, with a data cut-off date of July 10, 2020, may be found on the IGCS conference site at https://igcs.org/igcs-2020-abstracts/ on page 97 of the \"Digital Poster\" PDF and on Sutro's website; the IGCS poster will be available following market close on September 9, 2020.\nConference Call Information:To access the conference call and live audio webcast on Wednesday, Sept. 9, at 5:30 p.m. EDT, please dial (877) 407-8974 (domestic) or (201) 389-0894 (international).\nThe conference call will be webcast via the Investors page on the Company's website at ir.sutrobio.com. Approximately two hours following the live event, a webcast replay of the conference call will be available through the Company Presentation page of the Investor section of the company's website at www.sutrobio.com for approximately 30 days.\nWorld ADC Conference Three Sutro executives will also present at World ADC Digital 2020 being held Sept. 15-18, 2020. Dr. Hallam will present proof of concept data for a next generation dual conjugated combination immunostimulatory...